TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16278686

Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (2.14 g of DHA/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Corn oil (6 g)
Number of subjects: 27
Study: 15596875

Group type: EXPERIMENTAL
Intervention: iopamidol 340 (Niopam)
Number of subjects: 2019

Group type: COMPARATOR
Intervention: iobitridol 350 (Xenetix)
Number of subjects: 2019
Study: 11519638

Group type: EXPERIMENTAL
Intervention: Chronic nicotine treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acute nicotine treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 40
Study: 9222944

Group type: EXPERIMENTAL
Intervention: Carbidopa
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous saline infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7965876

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% 2-6 ml/h infusion through a catheter placed in the sciatic or posterior tibial nerve sheath
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (nonbupivacaine-treated patients)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bupivacaine treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 59
Study: 3662562

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in optimized vehicle (ointment)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30724012

Group type: EXPERIMENTAL
Intervention: Buddy-style intervention including physical training and nutritional support (n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 80
Study: 28579313

Group type: EXPERIMENTAL
Intervention: Probiotic soy milk (200 mL/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 48
Study: 25300782

Group type: EXPERIMENTAL
Intervention: Cranberry
Number of subjects: 192

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 192
Study: 23682595

Group type: EXPERIMENTAL
Intervention: High blood pressure (>120/80 mmHg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overweight (high BMI or waist circumference)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyslipidemia (low HDL-C, hypertriglyceridemia)
Number of subjects: 0
Study: 21953540

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study: 18067552

Group type: EXPERIMENTAL
Intervention: Stress management program (20 sessions of 2 hours each) and medical care by a cardiologist
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual health care (control group)
Number of subjects: 247
Study: 17211115

Group type: EXPERIMENTAL
Intervention: Essential oil group (aromatherapy with lavender, ylangylang, and bergamot, once daily for 4 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Catecholamine levels among the three groups
Number of subjects: 52
Study: 12845429

Group type: EXPERIMENTAL
Intervention: 30 mmol potassium phosphate in 50 ml saline over 2 h (Group 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 30 mmol potassium phosphate in 100 ml saline over 4 h (Group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 45 mmol potassium phosphate in 100 ml saline over 3 h (Group 3)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 45 mmol potassium phosphate in 100 ml saline over 6 h (Group 4)
Number of subjects: 47
Study: 11282702

Group type: EXPERIMENTAL
Intervention: Four-session interpersonal-therapy-oriented group intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Treatment-as-usual condition
Number of subjects: 37
Study: 9250849

Group type: EXPERIMENTAL
Intervention: Phenobarbital (10 mg/kg body weight, intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo (intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Number of subjects: 610
Study: 8413339

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ifosfamide plus Cisplatinum
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cisplatinum
Number of subjects: 79
Study: 3787198

Group type: EXPERIMENTAL
Intervention: Neodymium-YAG laser irradiation
Number of subjects: 122

Group type: COMPARATOR
Intervention: TUR
Number of subjects: 122
Study: 31556669

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 95
Study: 28720658

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Number of subjects: 13299

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13299

Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2-90)
Number of subjects: 13299
Study: 26227795

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich juice based on red grapes, cherries, chokeberries and bilberries
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich juice enriched with polyphenol-rich extracts from blackcurrant press-residue
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pooled juice group (both types of polyphenol-rich juices)
Number of subjects: 134
Study: 23744427

Group type: EXPERIMENTAL
Intervention: High-dose metformin (3 g daily in three divided doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21889078

Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 20
Study: 19401009

Group type: EXPERIMENTAL
Intervention: Structured lifestyle support
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Structured lifestyle support plus pedometer
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care plus pedometer
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 123
Study: 16420274

Group type: EXPERIMENTAL
Intervention: Canine retraction using 100 g sentalloy springs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control canine (contralateral side)
Number of subjects: 10
Study: 15530763

Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines (CPG) for assistive device use in home care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study: 11117374

Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg) and Verapamil (120-240 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Enalapril (10-20 mg)
Number of subjects: 18
Study: 9315788

Group type: EXPERIMENTAL
Intervention: Regular inhaled beta-agonist therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: As-needed inhaled beta-agonist therapy
Number of subjects: 70
Study: 8157042

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous infusion glucagon
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intramuscular glucagon
Number of subjects: 16
Study: 2872870

Group type: EXPERIMENTAL
Intervention: Family treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination of family treatment and social skills training
Number of subjects: 103

Group type: COMPARATOR
Intervention: Drug-treated condition (Control)
Number of subjects: 103
Study: 30513795

Group type: EXPERIMENTAL
Intervention: High-dose B-group vitamin supplementation
Number of subjects: 32
Study: 26796916

Group type: EXPERIMENTAL
Intervention: Exercise for Balance Improvement Program (ExBP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 61
Study: 24717247

Group type: EXPERIMENTAL
Intervention: Taper (desvenlafaxine 25 mg/d)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Abrupt discontinuation (placebo)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: No discontinuation (desvenlafaxine 50 mg/d)
Number of subjects: 357
Study: 22939979

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Programme (CBT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 133
Study: 20445353

Group type: EXPERIMENTAL
Intervention: Combined immunotherapy treatment with rIL-2 and IFN-alpha
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: NHL patients treated with immunotherapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: HL patients
Number of subjects: 109
Study: 17649770

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically zoledronate)
Number of subjects: 0
Study: 15629825

Group type: EXPERIMENTAL
Intervention: 2% gel twice daily (gel/gel)
Number of subjects: 353

Group type: COMPARATOR
Intervention: 2% gel daily (evening, placebo/gel)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Vehicle twice daily (placebo/placebo)
Number of subjects: 353
Study: 11973494

Group type: EXPERIMENTAL
Intervention: POM 1.0 mg/kg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: INM 0.4 mg/kg
Number of subjects: 129

Group type: COMPARATOR
Intervention: POD 0.5 mg/kg
Number of subjects: 129
Study: 10424986

Group type: EXPERIMENTAL
Intervention: Fourth-generation multiple-step systems
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fifth-generation single-bottle adhesives
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose and Single Bond adhesives
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: One‐Step and Optibond FL adhesives
Number of subjects: 48
Study: 7478701

Group type: EXPERIMENTAL
Intervention: Ketamine (0-40 mg, i.m., 8 times per day)
Number of subjects: 1
Study: 1519493

Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 200
Study: 6676926

Group type: EXPERIMENTAL
Intervention: diazepam/glucagon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: diazepam/atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pethidine/glucagon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pethidine/atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: atropine
Number of subjects: 0
Study: 29549496

Group type: EXPERIMENTAL
Intervention: n-6 docosapentaenoic acid (ObA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA, EPA, Omega-3 Index (O3I)
Number of subjects: 0
Study: 30234999

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) applied at tendon-to-bone interface
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 54
Study: 24793536

Group type: EXPERIMENTAL
Intervention: FF/VI (fluticasone furoate/vilanterol), 100/25 µg
Number of subjects: 26

Group type: COMPARATOR
Intervention: FF (fluticasone furoate), 100 µg
Number of subjects: 26
Study: 22540141

Group type: EXPERIMENTAL
Intervention: High-output VNS (1.75mA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low-output VNS (0.25mA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-output VNS (1.75mA) after initial phases
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall seizure severity
Number of subjects: 41
Study: 19953771

Group type: EXPERIMENTAL
Intervention: Home-bleaching (illumine Home, 10% carbamide peroxide, trays, overnight, for two weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In-office bleaching (Illumine Office, 15% hydrogen peroxide, trays for 45 minutes, three times over three weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Whitestrips (strips, twice a day, 30 minutes each for two weeks)
Number of subjects: 75
Study: 17300629

Group type: EXPERIMENTAL
Intervention: BCG revaccination at 19 months
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Control group (no revaccination)
Number of subjects: 1433
Study: 15673497

Group type: EXPERIMENTAL
Intervention: Design Fluency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word Fluency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tinker Toy Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Story Telling Tests
Number of subjects: 0
Study: 11148556

Group type: EXPERIMENTAL
Intervention: Low fat diet intervention with telephone counseling
Number of subjects: 1010

Group type: COMPARATOR
Intervention: General dietary guidelines to reduce disease risk (comparison group)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Both groups (total group)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Women with baseline BMI > or = 25 kg/m2
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 1010
Study: 9778302

Group type: EXPERIMENTAL
Intervention: Blom-Singer prosthesis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Provox prosthesis
Number of subjects: 52
Study: 7937384

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0
Study: 3281764

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.35 mg.kg‐1 bolus followed by 0.07 mg.kg‐1.hr‐1 infusion for 24 hr)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31963808

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum Q180 (LPQ180) for 12 weeks
Number of subjects: 70
Study: 30305252

Group type: EXPERIMENTAL
Intervention: Numbers + graphic representation + conceptual illustrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numbers only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numbers + graphic representation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numbers + conceptual illustrations
Number of subjects: 0
Study: 27765312

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 5845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5845
Study: 25076278

Group type: EXPERIMENTAL
Intervention: Ylang ylang essential oil by cutaneous application
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ylang ylang essential oil by inhalation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (ylang ylang essence through cutaneous application)
Number of subjects: 34
Study: 23332981

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Reduced injection frequency
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Concurrent decreased drug injection and increased alcohol consumption
Number of subjects: 629
Study: 20156209

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236

Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 236
Study: 19450093

Group type: EXPERIMENTAL
Intervention: High-dosage medical exercise therapy (HD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low-dosage medical exercise therapy (LD)
Number of subjects: 61
Study: 16686385

Group type: EXPERIMENTAL
Intervention: 2 mL of 2% lidocaine and adrenaline 1:200,000 (group I)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 4 mL of 1% lidocaine and adrenaline 1:400,000 (group II)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 4 mL of 1% lidocaine and adrenaline 1:200,000 (group III)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 4 mL of 1% lidocaine (group IV)
Number of subjects: 108
Study: 12839378

Group type: EXPERIMENTAL
Intervention: Triple therapy: lansoprazole 30 mg twice daily, amoxycillin 500 mg four times daily, clarithromycin 500 mg twice a day for 10 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Quadruple therapy: tri-potassium dicitrato bismuthate 120 mg four times daily, metronidazole 400 mg thrice daily, tetracycline 500 mg four times daily for 10 days
Number of subjects: 68
Study: 10791133

Group type: EXPERIMENTAL
Intervention: Albuterol plus prednisolone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Albuterol plus placebo
Number of subjects: 51
Study: 9025129

Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active compression-decompression CPR
Number of subjects: 12
Study: 1477847

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) with Sodium Valproate (VPA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) without Sodium Valproate (VPA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vigabatrin (GVG)
Number of subjects: 16
Study: 6742088

Group type: EXPERIMENTAL
Intervention: Asymmetrical tonic neck reflex (ATNR) in adults with hemiplegia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Method of rotation used to elicit the reflex
Number of subjects: 14
Study: 30625204

Group type: EXPERIMENTAL
Intervention: More cognitively demanding task
Number of subjects: 105

Group type: COMPARATOR
Intervention: Less cognitively demanding task
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Incentive to restrain drinking
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Implicit measures of alcohol-related associations
Number of subjects: 105
Study: 29668448

Group type: EXPERIMENTAL
Intervention: 15 mg of tranexamic acid per kg (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27333010

Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix Graft (ADMG) and Enamel Matrix Derivative (EMD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acellular Dermal Matrix Graft (ADMG) alone
Number of subjects: 19
Study: 24726066

Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy for 10 weeks according to national practice guidelines
Number of subjects: 191

Group type: COMPARATOR
Intervention: Usual care with no occupational therapy
Number of subjects: 191
Study: 23610854

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with sufentanil 0.5 microg/ml (group 1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% with sufentanil 0.5 microg/ml (group 2)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% with sufentanil 0.5 microg/ml (group 3)
Number of subjects: 63
Study: 20491746

Group type: EXPERIMENTAL
Intervention: PN 400 containing 30 mg esomeprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PN 400 containing 20 mg esomeprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PN 400 containing 10 mg esomeprazole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Naproxen plus esomeprazole 20 mg
Number of subjects: 28
Study: 17564755

Group type: EXPERIMENTAL
Intervention: 200 mg retarded release levodopa/carbidopa
Number of subjects: 13

Group type: COMPARATOR
Intervention: 150 mg levodopa/carbidopa/entacapone
Number of subjects: 13
Study: 16218781

Group type: EXPERIMENTAL
Intervention: Adenovirus‐delivered fibroblast growth factor‐4 (Ad5FGF‐4)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12049555

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10607255

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 125 mg (n = 15)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 125 mg
Number of subjects: 20
Study: 7829789

Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg twice daily
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg twice daily
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg twice daily
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1436
Study: 2162186

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation of retroperitoneal lymph nodes
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation group with pure embryonal carcinomas
Number of subjects: 156

Group type: COMPARATOR
Intervention: Observation group with vascular involvement
Number of subjects: 156
Study: 79764

Group type: EXPERIMENTAL
Intervention: Polyvalent pseudomonas vaccine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 38
Study: 30538070

Group type: EXPERIMENTAL
Intervention: IN Ketamine (1 ml = 50 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline, 1 ml)
Number of subjects: 100
Study: 27491438

Group type: EXPERIMENTAL
Intervention: Small aortic root
Number of subjects: 1560
Study: 25577501

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (6 sessions for children, 2 sessions for parents)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program
Number of subjects: 30
Study: 22926087

Group type: EXPERIMENTAL
Intervention: Fatigue assessment using the subscale of the Checklist Individual Strength, assessed monthly between T2 and T3.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Negative interactions, impaired sleep and rest, fatigue catastrophizing, and lower self-reported physical activity at T2.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.
Number of subjects: 60
Study: 21977863

Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoxetine (n = 40)
Number of subjects: 80